A5000572878- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- Asthma and respiratory diseases
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
- Allergic Rhinitis and Sensitization
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders Research
- Urticaria and Related Conditions
- Complementary and Alternative Medicine Studies
- Food Allergy and Anaphylaxis Research
- Monoclonal and Polyclonal Antibodies Research
- Nail Diseases and Treatments
- Cutaneous lymphoproliferative disorders research
- Contact Dermatitis and Allergies
- Health and Medical Studies
- Autoimmune and Inflammatory Disorders
- Cytokine Signaling Pathways and Interactions
- Immunotherapy and Immune Responses
- Drug-Induced Adverse Reactions
- Biosimilars and Bioanalytical Methods
- T-cell and B-cell Immunology
Universität Hamburg
2012-2025
University Medical Center Hamburg-Eppendorf
2012-2025
University Medical Center
2020-2024
John Wiley & Sons (United States)
2019-2022
John Wiley & Sons (United Kingdom)
2019-2022
Oxfam
2019-2022
Høyskolen Kristiania
2013-2022
Clinical Research Center Kiel
2022
DermResearch (United States)
2022
Dr. Reddy's Laboratories (United States)
2022
Interleukin-17A is considered to be central the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy Response and Safety Two Fixed Secukinumab Regimens Psoriasis) FIXTURE (Full Year Investigative Examination vs. Etanercept Using Dosing Determine Efficacy Psoriasis), we randomly assigned 738 (in study) 1306 subcutaneous...
Patients with moderate to severe psoriasis are undertreated. To solve this persistent problem, the consensus programme was performed define goals for treatment of plaque systemic therapy and improve patient care. An expert meeting a collaborative Delphi procedure were carried out. Nineteen dermatologists from different European countries met face-to-face discussion defined items through four-round process. Severity graded into mild disease. Mild disease as body surface area (BSA) ≤10...
Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo etanercept in the treatment moderate-to-severe psoriasis. We report 60-week data from UNCOVER-2 UNCOVER-3 trials, as well 12-week third trial, UNCOVER-1.We randomly assigned 1296 patients UNCOVER-1 1224 1346 trial receive subcutaneous injections (placebo group), 80 mg ixekizumab every 2 after starting dose 160 (2-wk dosing or 4...
JEADV october 2009, volume 23, supplement 2 European S3-Guidelines on the systemic treatment of psoriasis vulgaris D Pathirana, AD Ormerod, P Saiag, C Smith, PI Spuls, A Nast, J Barker, JD Bos, G-R Burmester, S Chimenti, L Dubertret, B Eberlein, R Erdmann, Ferguson, G Girolomoni, Gisondi, Giunta, Griffiths, H Hönigsmann, M Hussain, Jobling, S-L Karvonen, Kemeny, I Kopp, Leonardi, Maccarone, Menter, U Mrowietz, Naldi, T Nijsten, J-P Ortonne, H-D Orzechowski, Rantanen, K Reich, N Reytan,...
Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal antibody, was efficacious in psoriasis.We sought to assess efficacy and safety of guselkumab moderate severe psoriasis versus placebo adalimumab, including interrupted treatment switching adalimumab nonresponders guselkumab.Patients were randomized 100 mg (weeks 0 4, then every 8 weeks; n = 496); placebo→guselkumab 0, 12 at weeks 16 20; 248); or (80 week 40 1, 2 through 23; 248). At 28, 90% greater improvement...
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with similar safety in moderate severe plaque psoriasis (FIXTURE study).We sought directly compare and of secukinumab versus ustekinumab.In this 52-week, double-blind study (NCT02074982), 676 subjects were randomized 1:1 subcutaneous injection 300 mg or ustekinumab per label. Primary end point was 90% more improvement from baseline Psoriasis Area Severity Index (PASI) score (PASI...
Background Psoriasis is a common disease affecting all age groups. In contrast to adult psoriasis, only few studies on the epidemiology of childhood psoriasis have been published. Objectives Assessment prevalence and comorbidities juvenile in Germany based health insurance data. Methods Data were collected from database about 1·3 million nonselected individuals German statutory organization which covers geographical regions. Individuals with identified by ICD-10 codes applied outpatient...
Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) widely used, potent immunosuppressant but it not effective in all patients with atopic dermatitis, and side‐effects limit its use. Dupilumab, fully human anti‐interleukin 4 receptor‐alpha monoclonal antibody, inhibits signaling of IL‐4 IL‐13, key drivers Type 2/Th2‐mediated inflammation, approved the U.S.A. European Union for treatment inadequately‐controlled moderate‐to‐severe...
The interleukin‐17 cytokine family plays a central role in psoriasis pathogenesis. To evaluate the efficacy and safety of brodalumab, human anti‐interleukin‐17 receptor antibody, treating patients with moderate‐to‐severe plaque psoriasis. In this phase III, double‐blind, placebo‐controlled study (NCT01708590; AMAGINE‐1), adult U.S.A., Canada Europe were randomized to brodalumab (140 or 210 mg) placebo every 2 weeks (Q2W), an additional dose at week 1, for 12‐week induction phase. At 12,...
Because psoriatic arthritis (PsA) usually develops years after the first manifestation of skin symptoms, in many cases initial diagnosis PsA depends on dermatologist.To investigate prevalence and clinical pattern a daily practice population patients with psoriasis.Patients were enrolled an observational prospective cross-sectional cohort study at 48 community academic centres. Demographic medical parameters recorded, including severity symptoms (Psoriasis Area Severity Index, PASI), previous...
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.
Epidemiological studies indicate an increased risk of co-morbidities and association with other inflammatory diseases in psoriasis. However, most analyses have been performed on small samples patients. The aim this study was to evaluate the prevalence psoriasis based a large set health insurance data. database 1.3 million patients German nationwide statutory scheme analysed. Data-sets confirmed were extracted analysed for co-morbidities. Of 1,344,071 subjects, 33,981 had diagnosis...
Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids. Objectives To evaluate the efficacy safety of baricitinib patients moderate-to-severe AD who had inadequate response to therapies. Methods In two independent, multicentre, double-blind, III monotherapy trials, BREEZE-AD1 BREEZE-AD2, adults were randomized : once-daily placebo, mg, or 4 mg for 16 weeks....
BackgroundAtopic dermatitis is a chronic inflammatory skin disease characterized by pruritic lesions.ObjectiveWe sought to evaluate the safety and efficacy of multiple doses selective Janus kinase 1 inhibitor upadacitinib in patients with moderate severe atopic dermatitis.MethodsIn 16-week, double-blind, placebo-controlled, parallel-group, dose-ranging portion this 88-week trial 8 countries (ClinicalTrials.gov, NCT02925117; ongoing, not recruiting), adults inadequate control topical...